[go: up one dir, main page]

RU2013110844A - ANTIBODIES AGAINST IL-1β AND IL-18 USED FOR TREATMENT OF DISEASES - Google Patents

ANTIBODIES AGAINST IL-1β AND IL-18 USED FOR TREATMENT OF DISEASES Download PDF

Info

Publication number
RU2013110844A
RU2013110844A RU2013110844/10A RU2013110844A RU2013110844A RU 2013110844 A RU2013110844 A RU 2013110844A RU 2013110844/10 A RU2013110844/10 A RU 2013110844/10A RU 2013110844 A RU2013110844 A RU 2013110844A RU 2013110844 A RU2013110844 A RU 2013110844A
Authority
RU
Russia
Prior art keywords
antibody
disease
specified
binds
antibodies
Prior art date
Application number
RU2013110844/10A
Other languages
Russian (ru)
Inventor
ЛОКЕРЕН КАМПАГНЕ Менно ВАН
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2013110844A publication Critical patent/RU2013110844A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1. Способ лечения заболевания у пациента, где указанный способ включает введение указанному пациенту эффективного количества:а. биспецифического анти-IL-1β/IL-18 антитела; илиb. антитела, которое связывается с IL-1β и IL-18; илис. антитела, которое связывается с IL-1β, и антитела, которое связывается с IL-18;где указанное антитело или указанные антитела по пунктам а, b или с обладает/обладают способностью нейтрализовать или блокировать активность IL-1β и IL-18 в клетках или в тканях.2. Способ по п.1, где указанное антитело/указанные антитела является/являются гуманизированным(и).3. Способ по п.1, где указанное антитело по пункту (b) представляет собой антитело с двойной функцией.4. Способ по п.1, где по меньшей мере одно антитело по пункту (с) является моноклональным.5. Способ по п.1, где каждое антитело по пункту (с) является моноклональным.6. Способ по п.1, где антитела по пункту (с) вводят одновременно или последовательно.7. Способ по п.6, где указанные антитела вводят в течение 1 ч.8. Способ по п.1, где указанным заболеванием является иммунное заболевание, или аутоиммунное заболевание, или воспалительное, или аутовоспалительное заболевание.9. Способ по п.1, где указанным заболеванием является заболевание, опосредуемое инфламмасомой.10. Способ по п.1, где указанным заболеванием является заболевание, ассоциированное с IL-1β.11. Способ по п.1, где указанным заболеванием является заболевание, ассоциированное с IL-18.12. Способ по п.1, где указанным заболеванием является заболевание, ассоциированное с IL-1β/IL-18.13. Способ по п.8, где указанным заболеванием является возрастная дегенерация желтого пятна (ВДЖП).14. Способ по п.8, где указанным заболеванием является диабе�1. A method of treating a disease in a patient, wherein said method comprises administering to said patient an effective amount: a. a bispecific anti-IL-1β / IL-18 antibody; or b. antibodies that bind to IL-1β and IL-18; or with. an antibody that binds to IL-1β and an antibody that binds to IL-18; wherein said antibody or said antibodies according to a, b or c have / have the ability to neutralize or block the activity of IL-1β and IL-18 in cells or in tissues. 2. The method of claim 1, wherein said antibody (s) is / are humanized (s). The method of claim 1, wherein said antibody of (b) is an antibody with a double function. The method of claim 1, wherein the at least one antibody of (c) is monoclonal. The method of claim 1, wherein each antibody of (c) is monoclonal. The method of claim 1, wherein the antibodies of (c) are administered simultaneously or sequentially. The method according to claim 6, where these antibodies are administered for 1 h. The method of claim 1, wherein said disease is an immune disease, or an autoimmune disease, or an inflammatory or auto-inflammatory disease. The method of claim 1, wherein said disease is a disease mediated by an inflammasome. The method of claim 1, wherein said disease is a disease associated with IL-1β. The method of claim 1, wherein said disease is a disease associated with IL-18.12. The method of claim 1, wherein said disease is a disease associated with IL-1β / IL-18.13. The method of claim 8, wherein said disease is age-related macular degeneration (VDV). The method of claim 8, wherein said disease is diabetes

Claims (26)

1. Способ лечения заболевания у пациента, где указанный способ включает введение указанному пациенту эффективного количества:1. A method of treating a disease in a patient, wherein said method comprises administering to said patient an effective amount: а. биспецифического анти-IL-1β/IL-18 антитела; илиbut. a bispecific anti-IL-1β / IL-18 antibody; or b. антитела, которое связывается с IL-1β и IL-18; илиb. antibodies that binds to IL-1β and IL-18; or с. антитела, которое связывается с IL-1β, и антитела, которое связывается с IL-18;from. an antibody that binds to IL-1β and an antibody that binds to IL-18; где указанное антитело или указанные антитела по пунктам а, b или с обладает/обладают способностью нейтрализовать или блокировать активность IL-1β и IL-18 в клетках или в тканях.where the specified antibody or these antibodies according to paragraphs a, b or c has / have the ability to neutralize or block the activity of IL-1β and IL-18 in cells or tissues. 2. Способ по п.1, где указанное антитело/указанные антитела является/являются гуманизированным(и).2. The method according to claim 1, where the specified antibody / specified antibodies is / are humanized (s). 3. Способ по п.1, где указанное антитело по пункту (b) представляет собой антитело с двойной функцией.3. The method according to claim 1, where the specified antibody according to paragraph (b) is an antibody with a dual function. 4. Способ по п.1, где по меньшей мере одно антитело по пункту (с) является моноклональным.4. The method according to claim 1, where at least one antibody according to paragraph (C) is monoclonal. 5. Способ по п.1, где каждое антитело по пункту (с) является моноклональным.5. The method according to claim 1, where each antibody according to paragraph (C) is monoclonal. 6. Способ по п.1, где антитела по пункту (с) вводят одновременно или последовательно.6. The method according to claim 1, where the antibodies according to paragraph (C) are administered simultaneously or sequentially. 7. Способ по п.6, где указанные антитела вводят в течение 1 ч.7. The method according to claim 6, where these antibodies are administered for 1 hour 8. Способ по п.1, где указанным заболеванием является иммунное заболевание, или аутоиммунное заболевание, или воспалительное, или аутовоспалительное заболевание.8. The method according to claim 1, where the specified disease is an immune disease, or an autoimmune disease, or inflammatory, or auto-inflammatory disease. 9. Способ по п.1, где указанным заболеванием является заболевание, опосредуемое инфламмасомой.9. The method according to claim 1, where the specified disease is a disease mediated by aflammasoma. 10. Способ по п.1, где указанным заболеванием является заболевание, ассоциированное с IL-1β.10. The method according to claim 1, where the specified disease is a disease associated with IL-1β. 11. Способ по п.1, где указанным заболеванием является заболевание, ассоциированное с IL-18.11. The method according to claim 1, where the specified disease is a disease associated with IL-18. 12. Способ по п.1, где указанным заболеванием является заболевание, ассоциированное с IL-1β/IL-18.12. The method according to claim 1, where the specified disease is a disease associated with IL-1β / IL-18. 13. Способ по п.8, где указанным заболеванием является возрастная дегенерация желтого пятна (ВДЖП).13. The method according to claim 8, where the specified disease is age-related macular degeneration (VLD). 14. Способ по п.8, где указанным заболеванием является диабет типа 2 (T2D).14. The method of claim 8, wherein said disease is type 2 diabetes (T2D). 15. Способ по п.8, где указанным заболеванием является воспалительное заболевание кишечника (ВЗК).15. The method of claim 8, wherein said disease is an inflammatory bowel disease (IBD). 16. Способ по п.15, где указанным ВЗК является болезнь Крона (БК).16. The method according to clause 15, where the specified IBD is Crohn's disease (CD). 17. Способ по п.15, где указанным ВЗК является язвенный колит (ЯК).17. The method according to clause 15, where the specified IBD is ulcerative colitis (UC). 18. Способ по п.1, где указанный пациент не является восприимчивым к терапии анти-TNF антителом.18. The method according to claim 1, where the specified patient is not susceptible to therapy with anti-TNF antibody. 19. Способ лечения заболевания у пациента, где указанный способ включает введение указанному пациенту эффективного количества моноклонального антитела, которое связывается с IL-1β, и моноклонального антитела, которое связывается с IL-18.19. A method of treating a disease in a patient, wherein said method comprises administering to said patient an effective amount of a monoclonal antibody that binds to IL-1β and a monoclonal antibody that binds to IL-18. 20. Способ нейтрализации или блокирования активности IL-1β и/или IL-18 в клетках или тканях, где указанный способ включает контактирование указанных клеток или тканей с моноклональным антителом, которое связывается с IL-1β, и с моноклональным антителом, которое связывается с IL-18, и, тем самым, нейтрализацию или блокирование указанной активности.20. A method of neutralizing or blocking the activity of IL-1β and / or IL-18 in cells or tissues, wherein said method comprises contacting said cells or tissues with a monoclonal antibody that binds to IL-1β and a monoclonal antibody that binds to IL -18, and thereby neutralizing or blocking the specified activity. 21. Способ по п.19, где указанное моноклональное антитело, которое связывается с IL-1β, и указанное моноклональное антитело, которое связывается с IL-18, вводят одновременно или последовательно.21. The method of claim 19, wherein said monoclonal antibody that binds to IL-1β and said monoclonal antibody that binds to IL-18 are administered simultaneously or sequentially. 22. Способ по п.20, где указанные клетки подвергают одновременному или последовательному контактированию с указанным моноклональным антителом, которое связывается с IL-1β, и с указанным моноклональным антителом, которое связывается с IL-18.22. The method according to claim 20, where these cells are subjected to simultaneous or sequential contact with the specified monoclonal antibody that binds to IL-1β, and with the specified monoclonal antibody that binds to IL-18. 23. Антитело, которое нейтрализует или блокирует активность IL-1β и IL-18.23. An antibody that neutralizes or blocks the activity of IL-1β and IL-18. 24. Антитело по п.23, где указанное антитело является биспецифическим антителом.24. The antibody of claim 23, wherein said antibody is a bispecific antibody. 25. Антитело по п.23, где указанное антитело является гуманизированным антителом.25. The antibody according to item 23, where the specified antibody is a humanized antibody. 26. Антитело по п.23, где указанное антитело связывается с IL-1β и IL-18. 26. The antibody of claim 23, wherein said antibody binds to IL-1β and IL-18.
RU2013110844/10A 2010-08-13 2011-08-12 ANTIBODIES AGAINST IL-1β AND IL-18 USED FOR TREATMENT OF DISEASES RU2013110844A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37376010P 2010-08-13 2010-08-13
US61/373,760 2010-08-13
PCT/US2011/047532 WO2012021773A1 (en) 2010-08-13 2011-08-12 Antibodies to il-1beta and il-18, for treatment of disease

Publications (1)

Publication Number Publication Date
RU2013110844A true RU2013110844A (en) 2014-09-20

Family

ID=44511598

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013110844/10A RU2013110844A (en) 2010-08-13 2011-08-12 ANTIBODIES AGAINST IL-1β AND IL-18 USED FOR TREATMENT OF DISEASES

Country Status (9)

Country Link
EP (1) EP2603525A1 (en)
JP (1) JP2013537539A (en)
KR (1) KR20130100125A (en)
CN (2) CN103154032A (en)
BR (1) BR112013003279A2 (en)
CA (1) CA2808185A1 (en)
MX (1) MX2013001267A (en)
RU (1) RU2013110844A (en)
WO (1) WO2012021773A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707235B1 (en) * 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
HUE052342T2 (en) 2013-03-14 2021-04-28 Univ Laval Use of electroretinography (ERG) to assess psychiatric disorders
MX2015015784A (en) * 2013-05-17 2016-03-11 Genentech Inc Methods for diagnosing and treating inflammatory bowel disease.
CN103554264B (en) * 2013-11-05 2015-08-12 哈尔滨博翱生物医药技术开发有限公司 For bi-specific antibody and the application thereof of IL-1 β and IL-17A
JP6787888B2 (en) * 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Anti-IL-1 beta antibody and usage
AU2015345323A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
MX2017005642A (en) 2014-11-10 2017-07-24 Hoffmann La Roche Anti-ang2 antibodies and methods of use.
GB201815045D0 (en) * 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN110251657B (en) * 2019-06-14 2020-11-17 中山大学 Application of EBV BRLF1 and functional small peptide thereof in inhibiting activity of inflammatory corpuscles
CA3173341A1 (en) 2020-03-26 2021-09-30 Diamentis Inc. Systems and methods for processing retinal signal data and identifying conditions
US12441786B2 (en) 2020-11-18 2025-10-14 Novartis Ag Bispecific antibodies for use in treatment of NLRC4-GOF inflammasomapathy
CA3219360A1 (en) * 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
KR20240141832A (en) 2022-02-09 2024-09-27 다이아멘티스 인크. Systems and methods for collecting retinal stimulation and/or retinal signal data

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577300A (en) 1897-02-16 Printing-press
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4010989A (en) 1975-10-14 1977-03-08 American Hospital Supply Corporation Lockable drawer compartment
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
SE8505922D0 (en) 1985-12-13 1985-12-13 Kabigen Ab CONSTRUCTION OF AN IGG BINDING PROTEIN TO FACILITATE DOWNSTREAM PROCESSING USING PROTEIN ENGINEERING
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (en) 1988-06-21 1995-05-24 Genentech Inc THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF MYOCARD INFARTS.
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
EP0602126B1 (en) 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
DE69315847T2 (en) 1992-08-21 1998-06-25 Genentech Inc METHOD FOR TREATING A FAULT BROUGHT BY LFA-1
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PL174494B1 (en) 1992-11-13 1998-08-31 Idec Pharma Corp Therapeutic application of chimeric and radiotracer labelled antibodies, directed against the differentation antigen limited to human lymphocytes b, for treating lymphoma from lymphocytes b
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
DK0733207T3 (en) 1993-12-10 1998-04-20 Genentech Inc Methods for the diagnosis of allergy and screening of anti-allergy therapeutics
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0739214B1 (en) 1994-01-18 1998-03-18 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US5686070A (en) 1994-03-03 1997-11-11 Genentech, Inc. Methods for treating bacterial pneumonia
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
JPH11507535A (en) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド Antibodies and antibody fragments that suppress tumor growth
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997026912A2 (en) 1996-01-23 1997-07-31 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ATE267257T1 (en) 1996-11-27 2004-06-15 Genentech Inc HUMANIZED ANTIBODIES AGAINST CD11A
JP3957765B2 (en) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド Anti-VEGF antibody
JP4213224B2 (en) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド Method for producing multispecific antibody having heteromultimer and common component
EP1860187B1 (en) 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
ATE348163T1 (en) 1998-10-23 2007-01-15 Amgen Inc THROMBOPOIETIN SUBSTITUTE
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
BR0015224A (en) 1999-10-29 2002-07-09 Genentech Inc Isolated prostatic stem cell (psca) anti-antigen, monoclonal anti-psca antibody, isolated nucleic acid, expression vector, cell, host cell, antibody production method, in vitro method composition to kill a cancer cell that expresses psca , use of an anti-psca monoclonal antibody and industrialized article
WO2001049698A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
CN101062415A (en) * 2000-02-21 2007-10-31 应用研究系统Ars股份公司 Use of IL-18 inhibitors
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
CA2411374C (en) * 2000-06-29 2012-10-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2295228T3 (en) 2000-11-30 2008-04-16 Medarex, Inc. TRANSGROMIC TRANSCROMOSOMIC ROLLERS FOR THE PREPARATION OF HUMAN ANTIBODIES.
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
CN1970077A (en) 2001-05-11 2007-05-30 安姆根有限公司 Peptides and related molecules that bind to tall-1
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy chain antibody
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
RU2515108C2 (en) 2005-08-19 2014-05-10 Эббви Инк Immunoglobulin with double variable domains and its applications
US20090298764A1 (en) * 2006-03-15 2009-12-03 Regents Of The University Of Colorado Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases
RU2008144802A (en) * 2006-04-14 2010-05-20 Новартис АГ (CH) APPLICATION OF ANTIBODIES AGAINST IL-1 FOR TREATMENT OF EYE DISORDERS
PL2059533T3 (en) 2006-08-30 2013-04-30 Genentech Inc Multispecific antibodies
BRPI0812040A2 (en) * 2007-05-29 2014-10-21 Novartis Ag INDICATIONS FOR ANTI-IL-I-BETA THERAPY
EP2247310A4 (en) * 2008-01-30 2012-06-27 Abbott Lab Compositions and methods for crystallizing antibody fragments
WO2010028273A1 (en) * 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function

Also Published As

Publication number Publication date
CN103154032A (en) 2013-06-12
WO2012021773A1 (en) 2012-02-16
CN104474546A (en) 2015-04-01
CA2808185A1 (en) 2012-02-16
MX2013001267A (en) 2013-04-10
JP2013537539A (en) 2013-10-03
KR20130100125A (en) 2013-09-09
EP2603525A1 (en) 2013-06-19
BR112013003279A2 (en) 2016-06-14

Similar Documents

Publication Publication Date Title
RU2013110844A (en) ANTIBODIES AGAINST IL-1β AND IL-18 USED FOR TREATMENT OF DISEASES
RU2017137010A (en) ANTI-SEASAM6 ANTIBODIES AND THEIR APPLICATIONS
JP2014509510A5 (en)
RU2012119788A (en) BINDING IL-1 PROTEINS
PE20200862A1 (en) ANTI-TREM2 ANTIBODIES AND RELATED METHODS
RU2016100892A (en) ANTIBODIES AGAINST TWEAKR AND THEIR APPLICATION
HRP20170568T1 (en) Anti-ox40 antibodies and methods of using the same
RU2019118359A (en) ANTIBODY TO HUMAN CD73
EA201370105A1 (en) HUMAN ANTIBODIES AGAINST THE HUMAN TNF-LIKAND-1A (TL1A)
CN103172738A (en) IL-12/P40 binding proteins
RU2017127772A (en) HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS
CN101512008A (en) Interleukin-13 binding proteins
RU2015121755A (en) IL-6 ANTAGONISTS AND THEIR APPLICATION
JP2014534239A5 (en)
JP2014511179A5 (en)
NZ610734A (en) Human antibodies to the glucagon receptor
NZ629178A (en) Antibodies to matrix metalloproteinase 9
EA201490020A1 (en) SOLUBLE PROTEINS FOR USE AS THERAPEUTIC TOOLS
RU2014148502A (en) HUMAN ANTIBODIES TO FEL D1 AND WAYS OF THEIR APPLICATION
JP2015533795A5 (en)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2016509585A5 (en)
JP2015509962A5 (en)
JP2013537539A5 (en)
RU2015118180A (en) ANTIBODIES TO BETA AMYLOID

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160407